← Back to Search

Topical Agent

GT20029 Gel for Acne

Phase 1
Waitlist Available
Research Sponsored by Suzhou Kintor Pharmaceutical Inc,
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up stage 1 is about 22 days and stage 2 is about 35 days
Awards & highlights

Study Summary

This trial is testing a new drug for safety, tolerability, and how it is metabolized in healthy subjects and subjects with androgenetic alopecia or acne.

Eligible Conditions
  • Acne
  • Male Pattern Baldness

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~stage 1 is about 22 days and stage 2 is about 35 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and stage 1 is about 22 days and stage 2 is about 35 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Adverse event
Skin irritation assessments
To characterize the PK AUC of GT20029
+3 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: GT20029Experimental Treatment1 Intervention
Group II: GT20029 PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
GT20029 Gel
2022
Completed Phase 1
~130

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Suzhou Kintor Pharmaceutical Inc,Lead Sponsor
14 Previous Clinical Trials
2,720 Total Patients Enrolled
~38 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top